PMID- 37290187
OWN - NLM
STAT- MEDLINE
DCOM- 20230622
LR  - 20230622
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 164
DP  - 2023 Aug
TI  - Chronic inflammatory demyelinating polyradiculoneuropathy in patients with 
      diabetes mellitus - treatment with intravenous immunoglobulins: A systematic 
      review.
PG  - 114974
LID - S0753-3322(23)00764-3 [pii]
LID - 10.1016/j.biopha.2023.114974 [doi]
AB  - BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a 
      rare disease, but it is one of the most common inflammatory neuropathies in the 
      population. It is particularly common among patients with diabetes mellitus. This 
      raises many problems, both with the differential diagnosis of diabetic and 
      inflammatory neuropathy, as well as the choice of treatment. Intravenous 
      immunoglobulin (IVIG) is one of the therapeutic options. There is evidence for 
      the effectiveness of IVIG in treating about two-thirds of patients. However, no 
      review has been published to date systematising studies evaluating the response 
      to IVIG treatment in patients with CIDP and coexisting diabetes. METHODS: The 
      present study is based on the PRISMA statement and is registered at PROSPERO 
      (CRD42022356180). The study included searches of the databases of MEDLINE, ERIC, 
      CINAHL Complete, Academic Search Ultimate and Health Source: Nursing/Academic 
      Edition, finally including seven original papers evaluating a total of 534 
      patients in the review. The main inclusion criteria were the presence of a group 
      of patients with CIDP and comorbid diabetes in the study. RESULTS: The systematic 
      review showed a lower efficacy of IVIG treatment among patients with coexisting 
      diabetes compared with idiopathic CIDP (61 % vs 71 %). In addition, the presence 
      of conduction blocks on neurography and shorter disease duration proved to be 
      significant factors improving response to treatment. CONCLUSIONS: Current 
      scientific data do not allow for strong recommendations on the choice of 
      treatment for CIDP. A randomised, multicentre study evaluating the efficacy of 
      different therapeutic approaches to this disease entity needs to be planned.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Andrusiow, Szymon
AU  - Andrusiow S
AD  - Department of Neurology, Wroclaw Medical University, Wroclaw, Poland. Electronic 
      address: szymon0946@wp.pl.
FAU - Pawlak, Zuzanna
AU  - Pawlak Z
AD  - Department of Dermatology, Venereology and Allergology, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Stanczykiewicz, Bartlomiej
AU  - Stanczykiewicz B
AD  - Division of Consultation Psychiatry and Neuroscience, Department of Psychiatry, 
      Wroclaw Medical University, L. Pasteura 10, 50-367 Wroclaw, Poland.
FAU - Bogunia-Kubik, Katarzyna
AU  - Bogunia-Kubik K
AD  - Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute 
      of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, 
      Poland.
FAU - Koszewicz, Magdalena
AU  - Koszewicz M
AD  - Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20230607
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - *Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/drug 
      therapy/diagnosis
MH  - Infusions, Intravenous
MH  - Administration, Intravenous
MH  - *Diabetes Mellitus/drug therapy
MH  - Multicenter Studies as Topic
OTO - NOTNLM
OT  - Chronic inflammatory demyelinating polyradiculoneuropathy
OT  - Diabetes
OT  - Intravenous immunoglobulin
OT  - Systematic review
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/09 01:09
MHDA- 2023/06/22 06:41
CRDT- 2023/06/08 18:02
PHST- 2023/04/16 00:00 [received]
PHST- 2023/05/26 00:00 [revised]
PHST- 2023/05/30 00:00 [accepted]
PHST- 2023/06/22 06:41 [medline]
PHST- 2023/06/09 01:09 [pubmed]
PHST- 2023/06/08 18:02 [entrez]
AID - S0753-3322(23)00764-3 [pii]
AID - 10.1016/j.biopha.2023.114974 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2023 Aug;164:114974. doi: 10.1016/j.biopha.2023.114974. Epub 
      2023 Jun 7.